Please use this identifier to cite or link to this item:
http://hdl.handle.net/11054/1736
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor | Hossain, Mehrab E. | en_US |
dc.contributor | Lister, David | en_US |
dc.contributor | Bartolo, Caroline | en_US |
dc.contributor | Kinsella, Paul | en_US |
dc.contributor | Knox, James | en_US |
dc.contributor | Aldrich, Rosemary | en_US |
dc.contributor | Cowan, Raquel | en_US |
dc.contributor | Commons, Robert J. | en_US |
dc.date.accessioned | 2021-07-23T00:30:21Z | - |
dc.date.available | 2021-07-23T00:30:21Z | - |
dc.date.issued | 2021 | - |
dc.identifier.govdoc | 01702 | en_US |
dc.identifier.uri | http://hdl.handle.net/11054/1736 | - |
dc.description.abstract | Background The risk of transmission of Coronavirus Disease 2019 (COVID-19) is increasingly understood to be greatest early after symptom onset, however, factors associated with prolonged and increased risk of transmission remain unclear. In settings where COVID-19 prevalence is low, there may be a benefit of extending the period that patients are isolated to decrease the risk of transmission. This study explored the duration of viral shedding in such a location, in patients with mild-moderate COVID-19 disease in Ballarat, Australia. Methods Patients diagnosed with COVID-19 disease using a real-time reverse-transcriptase–polymerase-chain-reaction (RT-PCR) assay from oropharyngeal and bilateral deep nasopharyngeal sampling and managed through Ballarat Health Services between March 1 and May 1, 2020 were included. Patients were retested if they were afebrile for >72 hours, asymptomatic and >14 days since symptom onset. If positive on retesting, patients were tested every 3 to 7 days thereafter. Results Patients underwent testing a median of 4 days (range 1-12) after initial symptom onset. Duration of symptoms ranged from 1 to 36 days. Positive tests were recorded up to a median of day 21 (range 6-38). Cycle thresholds were inversely correlated with time since symptom onset (P < .0001). Median time to the first negative test was 25 days (range 12-32). Two patients who had remained asymptomatic for >7 days after initial symptom onset had recrudescence of mild symptoms on day 13 and 14; both tested positive on follow-up tests at this time. Conclusions This study demonstrates prolonged shedding of COVID-19 in patients with mild-moderate disease. It suggests that some patients with mild disease may have recrudescence of symptoms a week or more after their initial symptoms resolved. | en_US |
dc.description.provenance | Submitted by Gemma Siemensma (gemmas@bhs.org.au) on 2021-05-13T01:59:13Z No. of bitstreams: 0 | en |
dc.description.provenance | Approved for entry into archive by Gemma Siemensma (gemmas@bhs.org.au) on 2021-07-23T00:30:21Z (GMT) No. of bitstreams: 0 | en |
dc.description.provenance | Made available in DSpace on 2021-07-23T00:30:21Z (GMT). No. of bitstreams: 0 Previous issue date: 2021 | en |
dc.title | Prolonged viral shedding in patients with mild to moderate COVID-19 disease: A regional perspective . | en_US |
dc.type | Journal Article | en_US |
dc.type.specified | Article | en_US |
dc.bibliographicCitation.title | Infectious Diseases: Research and Treatment | en_US |
dc.bibliographicCitation.volume | 14 | en_US |
dc.bibliographicCitation.stpage | 1 | en_US |
dc.bibliographicCitation.endpage | 3 | en_US |
dc.subject.healththesaurus | COVID-19 | en_US |
dc.subject.healththesaurus | SARS-CoV-2 | en_US |
dc.subject.healththesaurus | SHEDDING | en_US |
dc.subject.healththesaurus | AUSTRALIA | en_US |
dc.subject.healththesaurus | MILD | en_US |
dc.identifier.doi | https://doi.org/10.1177/11786337211010428 | en_US |
Appears in Collections: | Research Output |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.